Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.8% – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was up 5.8% during mid-day trading on Monday . The stock traded as high as $28.49 and last traded at $28.4420. Approximately 689,063 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 2,157,991 shares. The stock had previously closed at $26.89.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of recent analyst reports. HC Wainwright upped their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer raised their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday. Industrial Alliance Securities set a $48.00 target price on shares of Capricor Therapeutics in a research note on Wednesday. Finally, Roth Capital increased their price target on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Up 10.6%

The company has a market capitalization of $1.36 billion, a P/E ratio of -16.60 and a beta of 0.62. The company’s 50 day moving average is $7.59 and its 200-day moving average is $8.22.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). Analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $28,000. Parkside Financial Bank & Trust bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $36,000. Russell Investments Group Ltd. raised its holdings in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,976 shares in the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in shares of Capricor Therapeutics in the first quarter worth approximately $95,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.